挪威带状疱疹疾病负担研究
该研究链接多个健康登记数据,量化挪威2008-2014年就医带状疱疹及1996-2012年相关死亡负担。共纳入82,064例患者,粗年发病率初级医疗227.1/10万、医院24.8/10万;≥50岁成人发病率更高(初级461/10万、医院57/10万),女性高于男性。结论认为就医带状疱疹构成显著负担,多数病例为≥50岁成人,增加疫苗接种或有必要。
要点
- 挪威2008-2014年共82,064例就医带状疱疹患者,粗年发病率初级医疗227.1/10万、医院24.8/10万。
- ≥50岁成人发病率初级医疗461/10万、医院57/10万,女性高于男性。
- 住院患者中47%有并发症、25%有合并症,中位住院4天,住院病死率1.04%。
核心结论
- 就医带状疱疹给挪威医疗部门带来沉重负担,多数病例为≥50岁成人,增加带状疱疹疫苗接种或有必要,尤其对合并症患者。
研究设计与样本
- 链接多个健康登记数据,识别2008-2014年挪威全人群就医带状疱疹病例及1996-2012年带状疱疹相关死亡。
- 按年龄、性别、就诊类型、疫苗接种状态及住院患者合并症计算发病率,并估计相关死亡率和病死率。
- 研究纳入82,064例带状疱疹患者,其中无一人报告接种过带状疱疹疫苗。
主要发现
- 带状疱疹粗年发病率初级医疗为227.1/10万,医院为24.8/10万。
- ≥50岁成人发病率初级医疗461/10万、医院57/10万;女性初级医疗267/10万 vs 男性188/10万,医院女性28/10万 vs 男性22/10万。
- 住院患者中47%有复杂性带状疱疹,25%按Charlson合并症指数有合并症;中位住院时间4天,随合并症严重程度增加而延长。
- 估计死亡率为0.18/10万,住院病死率为1.04%。
临床怎么用
- 作者认为增加带状疱疹疫苗接种或有必要,尤其对合并症患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No national vaccination program against herpes zoster (HZ) is currently in place in Norway. We aimed to quantify the burden of medically attended HZ to assess the need for a vaccination program. METHODS: We linked data from several health registries to identify medically attended HZ cases during 2008-2014 and HZ-associated deaths during1996-2012 in the entire population of Norway. We calculated HZ incidences for primary and hospital care by age, sex, type of health encounter, vaccination status, and co-morbidities among hospital patients. We also estimated HZ-associated mortality and case-fatality. RESULTS: The study included 82,064 HZ patients, of whom none were reported as vaccinated against HZ. The crude annual incidence of HZ was 227.1 cases per 100,000 in primary healthcare and 24.8 cases per 100,000 in hospitals. Incidence rates were higher in adults aged ≥50 years (461 per 100,000 in primary care and 57 per 100,000 in hospitals), and women than in men both in primary healthcare (267 vs 188 per 100,000), and hospitals (28 vs 22 per 100,000). Among hospital patients, 47% had complicated zoster and 25% had comorbidities, according to the Charlson comorbidity index. The duration of hospital stay (median 4 days) increased with the severity of comorbidities. The estimated mortality rate was 0.18 per 100,000; and in-hospital case-fatality rate was 1.04%. CONCLUSIONS: Medically attended HZ poses a substantial burden in the Norwegian healthcare sector. The majority of the zoster cases occurred among adults aged ≥50 years - the group eligible for zoster vaccination - and increased use of zoster vaccination may be warranted, especially among persons with co-morbidities.
引用
- Mirinaviciute G, Quist-Paulsen E, Brantsæter AB, et al. The burden of herpes zoster disease in Norway. Vaccine. 2019. PMID: 31843267. doi:10.1016/j.vaccine.2019.11.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。